Literature DB >> 11096490

Rheumatic Fever.

.   

Abstract

There have been numerous reports stating that treatment of acute rheumatic fever with either aspirin or corticosteroids does not alter the long-term outcome of rheumatic heart disease. Yet, it should be emphasized that most of these studies were carried out with the first generic corticosteroids before the advent of the more active and more potent corticosteroid agents. In spite of this caveat, there is no question that all the clinical and laboratory parameters of inflammation (erythrocyte sedimentation rate, C-reactive protein) return to normal much more rapidly with corticosteroids than with aspirin alone. It is therefore our belief that steroids should be used when clinical and laboratory evidence of carditis exists, and aspirin should be reserved for cases of acute rheumatic arthritis with no evidence of carditis. The incidence of long-term valvular disease in active carditis may be decreased with steroid therapy. For example, the number of valve replacements differs markedly in centers that do use steroids and in those that do not. In Capetown, South Africa, where steroids are routinely used for carditis, valve replacement is quite rare. In contrast, in Johannesburg, where steroids are rarely used, the rate of valve replacement is quite high. The racial backgrounds of both groups of patients are similar, thus eliminating the question of racial differences. Concerning secondary prophylaxis, there is also controversy concerning the best second-line therapy. It is now well known that monthly intramuscular injections of benzathine penicillin are really effective for only 20 days. Thus, there is a window in which penicillin coverage is not adequate. To circumvent this problem, some investigators give benzathine penicillin every 3 weeks. These injections are quite painful, however, and it has been our "rule" that compliance with this treatment is inversely proportional to the ratio of the size of the child to the mother. In our own experience over 30 years with the follow-up of more than 300 patients with acute rheumatic fever, careful discussion of the consequences of missing oral doses has been adequate to insure proper compliance. An analysis of our patients on oral penicillin prophylaxis compared with other groups using benzathine penicillin revealed that there was very little difference in recurrence rate.

Entities:  

Year:  1999        PMID: 11096490     DOI: 10.1007/s11936-999-0041-5

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  10 in total

1.  The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (Compound E) on the acute phase of rheumatic fever; preliminary report.

Authors:  P S HENCH; C H SLOCUMB
Journal:  Proc Staff Meet Mayo Clin       Date:  1949-05-25

2.  Prevention of rheumatic fever; treatment of the preceding streptococcic infection.

Authors:  F W DENNY; L W WANNAMAKER; W R BRINK; C H RAMMELKAMP; E A CUSTER
Journal:  J Am Med Assoc       Date:  1950-05-13

Review 3.  Rheumatic fever prevention in industrializing countries: problems and approaches.

Authors:  R Snitcowsky
Journal:  Pediatrics       Date:  1996-06       Impact factor: 7.124

Review 4.  Changing streptococci and prospects for the global eradication of rheumatic fever.

Authors:  G H Stollerman
Journal:  Perspect Biol Med       Date:  1997       Impact factor: 1.416

5.  Rheumatic carditis.

Authors:  G H Stollerman
Journal:  Lancet       Date:  1995-08-12       Impact factor: 79.321

6.  The treatment of rheumatic carditis: a review and meta-analysis.

Authors:  D A Albert; L Harel; T Karrison
Journal:  Medicine (Baltimore)       Date:  1995-01       Impact factor: 1.889

7.  Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study.

Authors:  X Berrios; E del Campo; B Guzman; A L Bisno
Journal:  Ann Intern Med       Date:  1993-03-15       Impact factor: 25.391

8.  Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  A S Dajani; K A Taubert; M Takahashi; F Z Bierman; M D Freed; P Ferrieri; M Gerber; S T Shulman; A W Karchmer; W Wilson
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

Review 9.  Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever?

Authors:  B J Currie
Journal:  Pediatrics       Date:  1996-06       Impact factor: 7.124

10.  Evidence for two distinct classes of streptococcal M protein and their relationship to rheumatic fever.

Authors:  D Bessen; K F Jones; V A Fischetti
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.